Novo Nordisk invests $100m to expand R&D facilities in China
Novo Nordisk is to invest 100 million US dollars to expand its state-of-the-art science facilities in Beijing, China. The new centre will allow an increase in the number of science employees, as well as providing extra space for further growth in the future.
The original site in Beijing has already contributed significantly to Novo Nordisk’s research and development portfolio, in both diabetes and biopharmaceutical target disease areas. As the world’s leading producer of insulin, Novo Nordisk hopes that its new, expanded facility will enable stronger contributions from the science team in China.
“We see the investment in this new R&,D facility as a win-win opportunity for both Novo Nordisk and China. Novo Nordisk recognises the strong science being performed in China and we want to bring innovation from Chinese scientists into our company to help tackle the growing burden of diabetes and other chronic diseases throughout the world.”
Mads Krogsgaard Thomsen, chief science officer and executive vice president, Novo Nordisk.
Danish Novo Nordisk has a long-term commitment to China, after becoming the first international biopharmaceutical company to open a research centre there in 1997.
Novo Nordisk Beijing science-park expansion opens (Market Watch)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.